Vanderbilt SCHolars in HIV and Heart, Lung, Blood, and Sleep ReSearch (V-SCHoLARS, K12)

范德比尔特艾滋病毒与心脏、肺、血液和睡眠研究学者(V-SCHoLARS,K12)

基本信息

项目摘要

With effective combination antiretroviral therapy (ART), people living with HIV/AIDS are living longer, but this success is tempered by rising rates of cardiopulmonary, hematologic, and sleep (HLBS) comorbidities in the HIV population. Vanderbilt University’s location in the Southeastern United States places it in the region with the highest rates incident HIV infection and cardiopulmonary disease. For these reasons, this application seeks to establish the Vanderbilt SCholars in HIV and Heart, Lung, Blood, And Sleep ReSearch (V-SCHoLARS, K12) program to train and mentor the next generation of HIV HLBS researchers with expertise in domains ranging from basic science to large population studies. We propose to support 5 junior faculty V-SCHoLARS who have completed an MD or PhD in the health sciences at a level of 75% effort for 2 years. Vanderbilt has a rich research environment and highly successful history of developing the careers of research scientists. Vanderbilt scholars in career development programs have an 84% success rate for extramural funding and a 70% K to R or R-equivalent conversion rate. Our proposed program, aided by Vanderbilt’s Office for Diversity Affairs, will recruit from a diverse pool of talented applicants through Vanderbilt's existing T32 grants; clinical/research fellowships in cardiovascular, pulmonary, hematology, and sleep medicine; the VA Quality Scholars Fellowship; and Meharry Medical College. Scholars will have access to 33 established NIH-funded mentors with expertise in HIV/infectious disease, cardiovascular, pulmonary, hematology, or sleep medicine who have a demonstrated track record of mentoring early career scholars, as well as 14 topic experts in the fields of basic science, clinical trials/translational research, population/epidemiology, health services/operational research, and biostatistics and bioinformatics. The program will have 4 major components: (1) formal mentoring (each scholar will have a paired HIV and an HLBS mentor), 2) didactic education that includes an opportunity to obtain a Master of Science in Clinical Investigation, 3) guaranteed protected time, and 4) a mentored research project that will be submitted as part of career development grant in year two. Each Scholar will have an individualized development plan with milestones tailored to their scientific background, training needs, and career goals. Scholars will have access to institutional resources including the Vanderbilt Institute for Clinical and Translational Research, the Tennessee Center for AIDS Research, existing cohort data (e.g., Veterans Aging Cohort Study), biostatistical support, 50 research cores, and BioVu, one of the world’s largest clinically linked biobanks. Scholars will also be supported by a range of career development resources: interdisciplinary expert consultant studios to vet scientific ideas, aims, and research designs; a K08/K23/R01 funded grant library; grant workshops; work-in-progress sessions; and research seminars through the Newman Society, a professional group for all career development awardees at Vanderbilt. Taken together, Vanderbilt provides an optimal environment for developing a diverse, well-trained next generation of HIV HLBS researchers.
通过有效的联合抗逆转录病毒治疗 (ART),艾滋病毒/艾滋病感染者的寿命更长,但这 心肺、血液和睡眠 (HLBS) 合并症发生率的上升阻碍了成功的实现 艾滋病毒人群。范德堡大学位于美国东南部,地理位置优越, 艾滋病毒感染和心肺疾病的发生率最高。由于这些原因,本申请寻求 建立艾滋病毒和心脏、肺、血液和睡眠研究领域的范德比尔特学者 (V-SCHoLARS, K12) 培训和指导下一代 HIV HLBS 研究人员的计划,这些研究人员具有以下领域的专业知识 从基础科学到大规模人口研究。我们建议支持 5 名初级教师 V-SCHoLARS,他们拥有 两年内以 75% 的努力完成了健康科学领域的医学博士或博士学位。范德比尔特拥有丰富的 研究环境和研究科学家职业发展的非常成功的历史。范德比尔特 职业发展项目的学者获得校外资助的成功率为 84%,K 到 R 的成功率为 70% 或 R 等效转化率。我们提议的计划在范德比尔特多元化事务办公室的协助下,将 通过范德堡大学现有的 T32 补助金从多元化的人才库中招募人才;临床/研究 心血管、肺、血液学和睡眠医学领域的研究金;弗吉尼亚州质量学者 奖学金;和梅哈里医学院。学者们将有机会接触 33 名 NIH 资助的导师 具有艾滋病毒/传染病、心血管、肺、血液学或睡眠医学方面的专业知识,并且有 展示了指导早期职业学者以及基础领域 14 名主题专家的记录 科学、临床试验/转化研究、人口/流行病学、卫生服务/运筹学、 以及生物统计学和生物信息学。该计划将包含 4 个主要组成部分:(1) 正式指导(每个部分 学者将有一对 HIV 导师和 HLBS 导师),2) 教学教育,包括有机会 获得临床研究理学硕士学位,3) 保证受保护时间,以及 4) 指导研究 该项目将作为第二年职业发展补助金的一部分提交。每个学者都会有一个 个性化的发展计划,其中包含根据其科学背景、培训需求和需求量身定制的里程碑 职业目标。学者将可以使用包括范德比尔特临床研究所在内的机构资源 和转化研究,田纳西州艾滋病研究中心,现有队列数据(例如,退伍军人 衰老队列研究)、生物统计支持、50 个研究核心以及 BioVu(世界上最大的临床研究之一) 链接的生物库。学者还将获得一系列职业发展资源的支持:跨学科 专家顾问工作室审查科学想法、目标和研究设计; K08/K23/R01 资助的赠款 图书馆;赠款讲习班;正在进行的工作会议;以及通过纽曼协会举办的研究研讨会 范德堡大学所有职业发展获奖者的专业团队。综上所述,范德比尔特提供了 培养多样化、训练有素的下一代 HIV HLBS 研究人员的最佳环境。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

MATTHEW S FREIBERG其他文献

MATTHEW S FREIBERG的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('MATTHEW S FREIBERG', 18)}}的其他基金

Microbiome, metabolites, and alcohol in HIV to reduce CVD RCT (META HIV CVD RCT)
HIV 中的微生物组、代谢物和酒精可减少 CVD 的随机对照试验 (META HIV CVD RCT)
  • 批准号:
    10685513
  • 财政年份:
    2021
  • 资助金额:
    $ 40.06万
  • 项目类别:
Administrative, Education, and Analytic Support Core
行政、教育和分析支持核心
  • 批准号:
    10304047
  • 财政年份:
    2021
  • 资助金额:
    $ 40.06万
  • 项目类别:
Microbiome, metabolites, and alcohol in HIV to reduce CVD RCT (META HIV CVD RCT)
HIV 中的微生物组、代谢物和酒精可减少 CVD 的随机对照试验 (META HIV CVD RCT)
  • 批准号:
    10685704
  • 财政年份:
    2021
  • 资助金额:
    $ 40.06万
  • 项目类别:
Microbiome, metabolites, and alcohol in HIV to reduce CVD RCT (META HIV CVD RCT)
HIV 中的微生物组、代谢物和酒精可减少 CVD 的随机对照试验 (META HIV CVD RCT)
  • 批准号:
    10304049
  • 财政年份:
    2021
  • 资助金额:
    $ 40.06万
  • 项目类别:
Administrative, Education, and Analytic Support Core
行政、教育和分析支持核心
  • 批准号:
    10685508
  • 财政年份:
    2021
  • 资助金额:
    $ 40.06万
  • 项目类别:
Vanderbilt SCHolars in HIV and Heart, Lung, Blood, and Sleep ReSearch (V-SCHoLARS, K12)
范德比尔特艾滋病毒与心脏、肺、血液和睡眠研究学者(V-SCHoLARS,K12)
  • 批准号:
    10429901
  • 财政年份:
    2018
  • 资助金额:
    $ 40.06万
  • 项目类别:
Vanderbilt SCHolars in HIV and Heart, Lung, Blood, and Sleep ReSearch (V-SCHoLARS, K12)
范德比尔特艾滋病毒与心脏、肺、血液和睡眠研究学者(V-SCHoLARS,K12)
  • 批准号:
    9761561
  • 财政年份:
    2018
  • 资助金额:
    $ 40.06万
  • 项目类别:
ST. PETER HIV-Alcohol, Protein Biomarkers and Cardiovascular Disease Risk
英石。
  • 批准号:
    9349871
  • 财政年份:
    2017
  • 资助金额:
    $ 40.06万
  • 项目类别:
ST. PETER HIV-Alcohol, Protein Biomarkers and Cardiovascular Disease Risk
英石。
  • 批准号:
    9770731
  • 财政年份:
    2017
  • 资助金额:
    $ 40.06万
  • 项目类别:
Immune function and the risk of cvd among HIV infected and uninfected veterans
HIV感染者和未感染者的免疫功能和CVD风险
  • 批准号:
    9268918
  • 财政年份:
    2014
  • 资助金额:
    $ 40.06万
  • 项目类别:

相似海外基金

RESEARCH SUPPORT SERVICES FOR THE DIVISION OF ACQUIRED IMMUNODEFICIENCY SYNDROME
获得性免疫缺陷综合症分类的研究支持服务
  • 批准号:
    10219039
  • 财政年份:
    2020
  • 资助金额:
    $ 40.06万
  • 项目类别:
RESEARCH SUPPORT SERVICES FOR THE DIVISION OF ACQUIRED IMMUNODEFICIENCY SYNDROME
获得性免疫缺陷综合症分类的研究支持服务
  • 批准号:
    9981476
  • 财政年份:
    2019
  • 资助金额:
    $ 40.06万
  • 项目类别:
IGF::OT::IGF RESEARCH SUPPORT SERVICES FOR THE DIVISION OF ACQUIRED IMMUNODEFICIENCY SYNDROME
IGF::OT::IGF 针对获得性免疫缺陷综合症分类的研究支持服务
  • 批准号:
    9364184
  • 财政年份:
    2016
  • 资助金额:
    $ 40.06万
  • 项目类别:
Human Immunodeficiency Virus (HIV) and Acquired Immunodeficiency Syndrome (AIDS) in Saskatchewan- Where are we now and what does the future hold?
萨斯喀彻温省的人类免疫缺陷病毒(HIV)和获得性免疫缺陷综合症(艾滋病)——我们现在在哪里以及未来会怎样?
  • 批准号:
    236932
  • 财政年份:
    2011
  • 资助金额:
    $ 40.06万
  • 项目类别:
    Miscellaneous Programs
ACQUIRED IMMUNODEFICIENCY SYNDROME RESEARCH REVIEW COMMI
获得性免疫缺陷综合症研究审查委员会
  • 批准号:
    3554155
  • 财政年份:
    1991
  • 资助金额:
    $ 40.06万
  • 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME REVIEW
获得性免疫缺陷综合症审查
  • 批准号:
    6766860
  • 财政年份:
    1991
  • 资助金额:
    $ 40.06万
  • 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME REVIEW
获得性免疫缺陷综合症审查
  • 批准号:
    6256640
  • 财政年份:
    1991
  • 资助金额:
    $ 40.06万
  • 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME RESEARCH REVIEW COMMI
获得性免疫缺陷综合症研究审查委员会
  • 批准号:
    3554156
  • 财政年份:
    1991
  • 资助金额:
    $ 40.06万
  • 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME RESEARCH REVIEW
获得性免疫缺陷综合症研究综述
  • 批准号:
    2063342
  • 财政年份:
    1991
  • 资助金额:
    $ 40.06万
  • 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME REVIEW
获得性免疫缺陷综合症审查
  • 批准号:
    6091256
  • 财政年份:
    1991
  • 资助金额:
    $ 40.06万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了